Blood Biomarkers for Breast Cancer Treatment Response
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Pittsburgh
About this trial
This study looks at whether a simple blood test can help predict how well a breast cancer treatment will work. It follows patients with advanced hormone receptor-positive breast cancer whose cancer has progressed after their first treatment.
Researchers collect a blood sample when patients start a second hormone therapy treatment and may collect additional samples over time. By comparing blood test results with patient outcomes, the study aims to identify biomarkers that can predict which patients are most likely to benefit from treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients must be ≥18 years of age
Clinical stage IV
HR positive
Progressing on first line treatment
Disqualifiers
None
Trial population
All patients with metastatic breast cancer refer to UPMC all sites
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
200 Participants
are grouped into 1 trial groupGroup A: breast cancer stage IV patients
Trial outcomes
Primary outcomes
1
To Assess the performance of the baseline PERDI score
Assessment of the performance of the baseline PERDI score, derived from plasma patients collected prior to the start of their second-line endocrine therapy (2L ET) using an epigenomics-based cell-free DNA (cfDNA) profiling assay, in predicting Progression-free survival (PFS).
Time frame
From the time between date of first day of 2L ET treatment and date of progression or death, whichever occurs first at 6 months or 1 yearSecondary outcomes
1
Assessment of the baseline modified PERDI score
Preform a prospective cross-study meta-analysis of both PERDI and modifies PERDI. Progression-free survival (PFS) will be compared between modified PERDI-positive and negative derived from plasma collected at the start of second line therapy using epigenomics- based cfDNA profiling assay.
Time frame
6 months or 1 year after start 2L therapySponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Pittsburgh
Lead sponsor
Precede Biosciences
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: